Iain Macpherson
Iain Macpherson
Institute of Cancer Sciences, University of Glasgow
Verified email at
Cited by
Cited by
Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression
MA Dozynkiewicz, NB Jamieson, I MacPherson, J Grindlay, ...
Developmental cell 22 (1), 131-145, 2012
Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry
VG Brunton, IRJ MacPherson, MC Frame
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1692 (2-3), 121-144, 2004
N-WASP coordinates the delivery and F-actin–mediated capture of MT1-MMP at invasive pseudopods
X Yu, T Zech, L McDonald, EG Gonzalez, A Li, I Macpherson, JP Schwarz, ...
Journal of cell biology 199 (3), 527-544, 2012
Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others
J Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ...
JNCI: Journal of the National Cancer Institute 108 (9), 2016
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
GD Demetri, PL Russo, IRJ MacPherson, D Wang, JA Morgan, ...
Clinical Cancer Research 15 (19), 6232-6240, 2009
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ...
The Lancet Oncology 20 (8), 1124-1135, 2019
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
A Serrels, IRJ Macpherson, TRJ Evans, FY Lee, EA Clark, OJ Sansom, ...
Molecular cancer therapeutics 5 (12), 3014-3022, 2006
Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice
H Cain, IR Macpherson, M Beresford, SE Pinder, J Pong, JM Dixon
Clinical Oncology 29 (10), 642-652, 2017
CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer
IR Macpherson, E Rainero, LE Mitchell, PVE van den Berghe, C Speirs, ...
Journal of cell science 127 (18), 3893-3901, 2014
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ...
The Lancet Oncology 21 (10), 1296-1308, 2020
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels
D Novo, N Heath, L Mitchell, G Caligiuri, A MacFarlane, D Reijmer, ...
Nature communications 9 (1), 1-17, 2018
p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism
IR Macpherson, S Hooper, A Serrels, L McGarry, BW Ozanne, ...
Oncogene 26 (36), 5214-5228, 2007
Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity
JR Hernandez-Fernaud, E Ruengeler, A Casazza, LJ Neilson, E Pulleine, ...
Nature communications 8 (1), 1-17, 2017
Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells
E Dornier, N Rabas, L Mitchell, D Novo, S Dhayade, S Marco, G Mackay, ...
Nature communications 8 (1), 1-14, 2017
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation
L Rooshenas, LJ Scott, JM Blazeby, CA Rogers, KM Tilling, S Husbands, ...
Journal of clinical epidemiology 106, 108-120, 2019
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ...
Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
CR Lindsay, IRJ MacPherson, J Cassidy
Future Medicine Ltd 5 (4), 421-432, 2009
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
G Argilés, MP Saunders, F Rivera, A Sobrero, CG Ponce, S Cascinu, ...
European journal of cancer 51 (8), 942-949, 2015
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study …
J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ...
European Journal of Cancer 82, 237-246, 2017
Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial
PS Hall, A Smith, C Hulme, A Vargas-Palacios, A Makris, ...
Value in Health 20 (10), 1311-1318, 2017
The system can't perform the operation now. Try again later.
Articles 1–20